{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:52:02Z","timestamp":1790085122183,"version":"4.0.1"},"reference-count":75,"publisher":"The Korean Association for the Study of the Liver","issue":"Suppl","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100022419","name":"NIHR Southampton Biomedical Research Centre","doi-asserted-by":"crossref","award":["IS-BRC-20004"],"award-info":[{"award-number":["IS-BRC-20004"]}],"id":[{"id":"10.13039\/501100022419","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000739","name":"University of Southampton","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-cmh.org"],"crossmark-restriction":true},"short-container-title":["Clin Mol Hepatol"],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:p>In the last 20 years, noninvasive serum biomarkers to identify liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) have been developed, validated against liver biopsy (the gold standard for determining the presence of liver fibrosis) and made available for clinicians to use to identify \u2265F3 liver fibrosis. The aim of this review is firstly to focus on the current use of widely available biomarkers and their performance for identifying \u2265F3. Secondly, we discuss whether noninvasive biomarkers have a role in identifying F2, a stage of fibrosis that is now known to be a risk factor for cirrhosis and overall mortality. We also consider whether machine learning algorithms offer a better alternative for identifying individuals with \u2265F2 fibrosis. Thirdly, we summarise the utility of noninvasive serum biomarkers for predicting liver related outcomes (e.g., ascites and hepatocellular carcinoma) and non-liver related outcomes (e.g., cardiovascular-related mortality and extra hepatic cancers). Finally, we examine whether serial measurement of biomarkers can be used to monitor liver disease, and whether the use of noninvasive biomarkers in drug trials for non-alcoholic steatohepatitis can accurately, compared to liver histology, monitor liver fibrosis progression\/regression. We conclude by offering our perspective on the future of serum biomarkers for the detection and monitoring of liver fibrosis in NAFLD.<\/jats:p>","DOI":"10.3350\/cmh.2022.0348","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T19:42:48Z","timestamp":1669146168000},"page":"S157-S170","update-policy":"https:\/\/doi.org\/10.3350\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future"],"prefix":"10.3350","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2436-1906","authenticated-orcid":true,"given":"Tina","family":"Reinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1902","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.891963"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.06.010"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.12.006"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0237"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314924"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.08.019"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00165-0"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01693.x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.052"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21669"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21496"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50346"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1476-5926-3-8"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30842"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14219"},{"key":"ref19","volume-title":""},{"key":"ref20","volume-title":""},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2021.0178"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14484"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00261-2"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpo.2021.0145"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2020.03.003"},{"key":"ref26","first-page":"63","volume-title":"Effect of exercise on hepatic steatosis: are benefits seen without dietary intervention? a systematic review and metaanalysis","author":"Baker","year":"2021"},{"key":"ref27","first-page":"2184","volume-title":"Obeticholic acid for the treatment of nonalcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","author":"Younossi","year":"2019"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8936865"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0181"},{"key":"ref30","volume-title":"Performance of the enhanced liver fibrosis (ELF) score, comparison with vibration-controlled transient elastography (VCTE) data, and development of a simple algorithm to predict significant liver fibrosis in a community-based liver service: a retrospective evaluation","author":"Reinson"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29302"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112415"},{"key":"ref34","volume-title":""},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.036"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121920"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32545"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06998-8"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.35712\/aig.v3.i3.80"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15385"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.043"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202393"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14448"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14669"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v14.i5.1025"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.004"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.203166"},{"key":"ref49","volume-title":""},{"key":"ref50","volume-title":""},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.06.007"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15255"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2021.0127"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0261"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-022-01860-0"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.024"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61933-4"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0907929"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.7326\/m15-1774"},{"key":"ref60","first-page":"9","volume-title":"One-year results of the global phase 2b randomized placebo-controlled ARREST trial of aramchol, a stearoyl CoA desaturasemodulator in NASH patients","author":"Ratziu","year":"2018"},{"key":"ref61","first-page":"11","volume-title":"RESOLVE-IT phase 3 of elafibranor in NASH: final results of the week 72 interim surrogate efficacy analysis","author":"Harrison","year":"2020"},{"key":"ref62","first-page":"11","volume-title":"A 52-week multi-center double-blind randomized phase 2 study of seladelpar, a potent and selective peroxisome proliferator- activated receptor delta (PPAR-delta) agonist, in patients with nonalcoholic steatohepatitis (NASH)","author":"Harrison","year":"2020"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2028395"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29477"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2036205"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.023"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00803-x"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.004"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01425-3"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32517-6"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.038"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.296"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31622"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.027"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29514"}],"container-title":["Clinical and Molecular Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2022-0348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2022.0348","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2022-0348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:11:58Z","timestamp":1678752718000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2022.0348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":75,"journal-issue":{"issue":"Suppl","published-print":{"date-parts":[[2023,2]]}},"URL":"https:\/\/doi.org\/10.3350\/cmh.2022.0348","relation":{},"ISSN":["2287-2728","2287-285X"],"issn-type":[{"value":"2287-2728","type":"print"},{"value":"2287-285X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"2022-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-22","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}